Gossamer Bio Stock

Gossamer Bio EBIT

The EBIT of Gossamer Bio (GOSS) as of Aug 3, 2026 is -161.44 M USD. In the previous year, EBIT was -59.92 M USD — a change of 169.43% (lower).

EBIT

-161.44 MUSD

YoY

169.43%

Last updated:

In 2026, Gossamer Bio's EBIT was -161.44 M USD, a 169.43% increase from the -59.92 M USD EBIT recorded in the previous year.

The Gossamer Bio EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-183.76 base
Jan 1, 2024
-59.92 base
Jan 1, 2025
-161.44 base
Jan 1, 2026 (e)
11.77 base
Jan 1, 2027 (e)
17.12 base
Jan 1, 2028 (e)
42.77 base
Jan 1, 2029 (e)
78.04 base
Jan 1, 2030 (e)
114.13 base
YEAREBIT (M USD)
2030 est 114.13
2029 est 78.04
2028 est 42.77
2027 est 17.12
2026 est 11.77
2025 -161.44
2024 -59.92
2023 -183.76
2022 -217.08
2021 -215.33
2020 -230.69
2019 -186.14
2018 -148.99
2017 -6.65
2016 -0.08
Access this data via the Eulerpool API

Gossamer Bio Revenue

Gossamer Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-183.76 M USD
-179.82 M USD
Jan 1, 2024
114.70 M USD
-59.92 M USD
-56.53 M USD
Jan 1, 2025
48.47 M USD
-161.44 M USD
-170.37 M USD
Jan 1, 2026 (e)
36.44 M USD
11.77 M USD
-90.49 M USD
Jan 1, 2027 (e)
53.00 M USD
17.12 M USD
-21.09 M USD
Jan 1, 2028 (e)
132.40 M USD
42.77 M USD
11.43 M USD
Jan 1, 2029 (e)
241.56 M USD
78.04 M USD
40.22 M USD
Jan 1, 2030 (e)
353.27 M USD
114.13 M USD
49.36 M USD

Gossamer Bio Margins

Gossamer Bio stock margins

The Gossamer Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gossamer Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gossamer Bio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
97.93 %
- %
- %
Jan 1, 2024
100.00 %
-52.24 %
-49.28 %
Jan 1, 2025
97.93 %
-333.06 %
-351.49 %
Jan 1, 2026 (e)
97.93 %
32.31 %
-248.36 %
Jan 1, 2027 (e)
97.93 %
32.31 %
-39.79 %
Jan 1, 2028 (e)
97.93 %
32.31 %
8.63 %
Jan 1, 2029 (e)
97.93 %
32.31 %
16.65 %
Jan 1, 2030 (e)
97.93 %
32.31 %
13.97 %

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Gossamer Bio's EBIT

Gossamer Bio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Gossamer Bio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Gossamer Bio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Gossamer Bio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Gossamer Bio stock

EBIT of Gossamer Bio is -161.44 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Gossamer Bio

All Key Metrics — Gossamer Bio